Fenfluramine: Clinical Trials

24 trials of Fenfluramine, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 completed, 4 recruiting, 3 terminated, 2 approved for marketing. 10 Phase 3, 4 Phase 2, 4 Phase 4, 2 Phase 1, 1 Not applicable.

By phase and status

PhaseTrialsStatus
Phase 310Completed 6, Terminated 2, Active not recruiting 1, Recruiting 1
Phase 24Completed 3, Recruiting 1
Phase 44Completed 2, Recruiting 2
Phase 12Completed 1, Terminated 1
Not applicable1Not yet recruiting 1

Follow Fenfluramine: new trials by email Literature Review of Fenfluramine trials Research Report on Fenfluramine

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 3 Study of Fenfluramine Hydrochloride in Rett Syndrome
fenfluramine hydrochloride, Placebo - Rett Syndrome
Phase 3RecruitingUCB BIOSCIENCES, Inc.2002026-07-142026-11-02
Using Fenfluramine to Test the Serotonin Deficiency Theory of Depression
Fenfluramine Hydrochloride, [11C]Cimbi-36, Placebo - Depression - Major Depressive Disorder
Not applicableNot yet recruitingImperial College Healthcare NHS Trust462026-07-012026-06-16
EEG Dynamics in Lennox-Gastaut Syndrome Patients Undergoing Fenfluramine Treatment
fenfluramine HCl - Lennox Gastaut Syndrome (LGS)
Enrolling by invitationUniversity of Chicago202026-05-012026-08-06
The FINTEPLA as an Anti-SUDEP Therapy in Dravet Syndrome Project
Fenfluramine treatment (Fintepla), Hypercapnia Challenge using the device (RespirAct) - Dravet Syndrome
Phase 4RecruitingThe University of Texas Health Science Center, Houston252026-04-272026-07-15
A Study to Assess Drug-drug Interaction of ZX008 in Healthy Male and Female Study Participants
midazolam, metformin, bupropion - Healthy Study Participants
Phase 1CompletedUCB BIOSCIENCES, Inc.222024-12-042026-07-02
Assessment of Safety of the Use of Fenfluramine in Children With Dravet Syndrome Under 24 Months of Age
fenfluramine - Dravet Syndrome (DS), Children Under 2 Years
Phase 4RecruitingUniversity of Colorado, Denver52024-10-222026-05-15
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Fenfluramine (Hydrochloride) in Infants 1 Year to Less Than 2 Years of Age With Dravet Syndrome
fenfluramine - Dravet Syndrome
Phase 3CompletedUCB BIOSCIENCES, Inc.252024-05-212026-09-17
Treatment of Refractory Infantile Spasms With Fenfluramine
Fenfluramine - Infantile Spasm
Phase 2RecruitingChildren's Hospital of Orange County102023-06-162026-04-15
Fenfluramine for Adult Dravet Patients
Fenfluramine - Dravet Syndrome, Dravet Syndrome, Intractable
Phase 3TerminatedUniversity Health Network, Toronto72023-01-112026-05-05
Fenfluramine for the Treatment of Different Types of Developmental and Epileptic Encephalopathies: a Pilot Trial Exploring Epileptic and Non-epileptic Outcomes
Fenfluramine - Refractory Epilepsy, SYNGAP1 Encephalopathy
Phase 4CompletedHospital Ruber Internacional202022-10-202026-09-29
A Phase 3 Study to Examine the Efficacy and Safety of ZX008 in Subjects With CDKL5 Deficiency Disorder.
Fenfluramine, Placebo - CDKL5 Deficiency Disorder, Generalized Tonic Clonic Seizure
Phase 3Active not recruitingZogenix, Inc.872022-03-082026-04-29
Fenfluramine and Cognition
Fenfluramine, Placebo - Cognitive Function
Phase 4CompletedUniversity of Oxford562021-04-122022-11-15
Fenfluramine in CDKL5 Deficiency Disorder (CDD)
Fenfluramine Hydrochloride - CDD
Phase 2CompletedNYU Langone Health72019-10-292023-10-04
Treatment of Sunflower Syndrome With ZX008 (Fenfluramine Hydrochloride) in Children and Young Adults (Ages 4-25).
Fenfluramine Hydrochloride - Photosensitive Epilepsy
Phase 3CompletedElizabeth Anne Thiele202019-05-312024-11-06
A Study to Investigate the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution in Children and Adults With Epileptic Encephalopathy Including Dravet Syndrome and Lennox-Gastaut Syndrome
ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome, Lennox Gastaut Syndrome
Phase 3CompletedZogenix, Inc.4122019-04-222025-11-17
A Study to Assess the Usability of the Embrace Seizure Detection Watch in Children and Young Adults With Dravet Syndrome
ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome
Phase 3TerminatedZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.52017-07-122023-11-13
A 2-Part Study to Investigate the Dose-Ranging Safety and Pharmacokinetics, Followed by the Efficacy and Safety of ZX008 (Fenfluramine Hydrochloride) Oral Solution as an Adjunctive Therapy in Children ≥ 2 Years Old and Young Adults With Dravet Syndrome
ZX008 (Fenfluramine Hydrochloride), Matching Placebo - Dravet Syndrome
Phase 3CompletedZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.872017-01-272022-11-02
An Open-Label Extension Trial to Assess the Long-Term Safety of ZX008 (Fenfluramine Hydrochloride HCl) Oral Solution in Children and Young Adults With Dravet Syndrome
ZX008 (Fenfluramine Hydrochloride) - Dravet Syndrome
Phase 3CompletedZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.3752016-06-082025-07-14
A Trial of Two Fixed Doses of ZX008 (Fenfluramine HCl) in Children and Young Adults With Dravet Syndrome
ZX008 (Fenfluramine Hydrochloride), Matching Placebo - Dravet Syndrome, Seizure Disorder
Phase 3CompletedZogenix International Limited, Inc., a subsidiary of Zogenix, Inc.2622016-01-152023-09-28
Add-on Therapy With Low Dose Fenfluramine in Lennox Gastaut Epilepsy
Fenfluramine - Epilepsy, Lennox Gastaut Syndrome
Phase 2CompletedKU Leuven132016-01-012026-10-20

Showing 20 of 24. Sign in to see all of them.

Conditions studied

Epilepsies, Myoclonic (12)  ·  Epilepsy (8)  ·  Brain Diseases (5)  ·  Seizures (5)  ·  Lennox Gastaut Syndrome (3)  ·  Spasms, Infantile (2)  ·  CDKL5 deficiency disorder (1)  ·  Chromosome 15q, tetrasomy (1)  ·  Cocaine-Related Disorders (1)  ·  Depressive Disorder, Major (1)  ·  Drug Resistant Epilepsy (1)  ·  Epilepsy, Reflex (1)  ·  Epilepsy, Tonic-Clonic (1)  ·  Epileptic Encephalopathy, Early Infantile, 4 (1)  ·  Genetic Diseases, Inborn (1)

Sponsors

Zogenix International Limited, Inc., a subsidiary of Zogenix, Inc. (4)  ·  UCB BIOSCIENCES, Inc. (3)  ·  Zogenix, Inc. (3)  ·  Children's Hospital of Orange County (1)  ·  Elizabeth Anne Thiele (1)  ·  Hospital Ruber Internacional (1)  ·  Imperial College Healthcare NHS Trust (1)  ·  KU Leuven (1)  ·  NYU Langone Health (1)  ·  National Heart, Lung, and Blood Institute (NHLBI) (1)  ·  National Institute on Drug Abuse (NIDA) (1)  ·  The University of Texas Health Science Center, Houston (1)  ·  University Health Network, Toronto (1)  ·  University of California, Los Angeles (1)  ·  University of Chicago (1)

Countries

United States (17)  ·  United Kingdom (9)  ·  Belgium (7)  ·  Germany (7)  ·  Spain (7)  ·  Italy (6)  ·  Canada (5)  ·  France (5)  ·  Japan (4)  ·  Netherlands (4)  ·  Australia (3)  ·  Denmark (3)  ·  Georgia (2)  ·  Israel (2)  ·  Poland (2)

Top investigators

Antonio Gil-Nagel, MD, PHD (1)  ·  Catherine J Harmer, DPhil (1)  ·  Daniel Shrey, MD (1)  ·  David Nutt, Professor (1)  ·  Elizabeth Thiele, M.D., Ph.D. (1)  ·  Kelly Knupp, MD (1)  ·  Laure Buydens-Branchey, M.D. (1)  ·  Lieven G Lagae, MD, PhD (1)  ·  Orrin Devinsky, MD (1)  ·  Phillip Cowen, Professor (1)  ·  Samden Lhatoo, MD, FRCP (1)

Results publications

PMID 34768178, PMID 33540241, PMID 30146701, PMID 31790543, PMID 31862249, PMID 33979451, PMID 34676542, PMID 36562419, PMID 37543865, PMID 39122687, PMID 40072476

NIH funding

2016 (1), 2019 (1), 2023 (1), 2025 (1), R01HL029188 (1)